Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5

[1]  Keith A. Johnson,et al.  Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β , 2017, Alzheimer's & Dementia.

[2]  Paul S. Aisen,et al.  Cross-validation of optimized composites for preclinical Alzheimer's disease , 2016, Alzheimer's & dementia.

[3]  Keith A. Johnson,et al.  Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. , 2016, Neuropsychology.

[4]  P. Snyder,et al.  Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score , 2015, Alzheimer's & dementia.

[5]  Stephen M. Rao,et al.  Genetic risk for Alzheimer's disease alters the five-year trajectory of semantic memory activation in cognitively intact elders , 2015, NeuroImage.

[6]  Keith A. Johnson,et al.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. , 2014, JAMA neurology.

[7]  Kewei Chen,et al.  An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[8]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[9]  Rebecca A Betensky,et al.  Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease , 2014, Neurology.

[10]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[11]  Yaakov Stern,et al.  Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review , 2013, Alzheimer's Research & Therapy.

[12]  S. Gauthier,et al.  Early-onset dementias: diagnostic and etiological considerations , 2013, Alzheimer's Research & Therapy.

[13]  L. Kuller,et al.  Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia , 2013, Neurology.

[14]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[15]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[16]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[17]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[18]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  E. Barbeau,et al.  The cognitive and neural expression of semantic memory impairment in mild cognitive impairment and early Alzheimer's disease , 2010, Neuropsychologia.

[20]  J. Teresi,et al.  The Free and Cued Selective Reminding Test: evidence of psychometric adequacy , 2009 .

[21]  H. Amièva,et al.  Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms , 2008, Annals of neurology.

[22]  T. Sunderland,et al.  Apolipoprotein E and category fluency: evidence for reduced semantic access in healthy normal controls at risk for developing Alzheimer's disease , 2005, Neuropsychologia.

[23]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[24]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[25]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[26]  R. Ivnik,et al.  An empirically derived short form of the Boston naming test. , 1999, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[27]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[28]  B. Reed,et al.  Age and education correction of Mini-Mental State Examination for English- and Spanish-speaking elderly , 1996, Neurology.

[29]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[30]  N Butters,et al.  Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. , 1992, Archives of neurology.

[31]  N Butters,et al.  Episodic and semantic memory: a comparison of amnesic and demented patients. , 1987, Journal of clinical and experimental neuropsychology.

[32]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[33]  A. Venneri,et al.  Paradigm shift: semantic memory decline as a biomarker of preclinical Alzheimer's disease. , 2016, Biomarkers in medicine.

[34]  Draft Guidance.  Guidance for Industry Alzheimer ’ s Disease : Developing Drugs for the Treatment of Early Stage Disease DRAFT GUIDANCE , 2013 .

[35]  Paul M Thompson,et al.  Cortical thickness and semantic fluency in Alzheimer's disease and mild cognitive impairment. , 2013, American journal of Alzheimer's disease.

[36]  Mei Sheng-hu,et al.  Guidance for industry of Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease , 2013 .

[37]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[38]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[39]  D. Wechsler.  WAIS-R manual : Wechsler adult intelligence scale-revised , 1981 .